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Pancreatic cancer carries a poor prognosis as most patients present with advanced
disease and preferred chemotherapy regimens offer only modest effects on survival.
Risk factors include smoking, obesity, heavy alcohol, and chronic pancreatitis. Pancreatic
cancer has a complex relationship with diabetes, as diabetes can be both a risk factor
for pancreatic cancer and a result of pancreatic cancer. Insulin, insulin-like growth
factor-1 (IGF-1), and certain hormones play an important role in promoting neoplasia
in diabetics. Metformin appears to reduce risk for pancreatic cancer and improve
survival in diabetics with pancreatic cancer primarily by decreasing insulin/IGF signaling,
disrupting mitochondrial respiration, and inhibiting the mammalian target of rapamycin
(mTOR) pathway. Other potential anti-tumorigenic effects of metformin include the
ability to downregulate specificity protein transcription factors and associated genes,
alter microRNAs, decrease cancer stem cell proliferation, and reduce DNA damage and
inflammation. Here, we review the most recent knowledge on risk factors and treatment
of pancreatic cancer and the relationship between diabetes, pancreatic cancer, and
metformin as a potential therapy.
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INTRODUCTION
EPIDEMIOLOGY
Pancreatic cancer is the twelfth most common cancer in the
US but represents the fourth leading cause of cancer death in
both men and women (Howlader et al., 2014). The prognosis is
extremely poor with a 5-year survival rate of only 6.7% as pancre-
atic cancer is usually asymptomatic in the early stages of disease
and most cases are diagnosed relatively late (Howlader et al.,
2014). Treatment and advances in early detection are of crucial
importance.
RISK FACTORS
Smoking is a well-known risk factor for pancreatic cancer and
is estimated to contribute to 20–30% of all cases of pancreatic
cancer (Iodice et al., 2008). A meta-analysis including 82 stud-
ies showed that smokers have a 75% increased risk of pancreatic
cancer compared to non-smokers and that the increased risk per-
sists at least 10 years after smoking cessation (Iodice et al., 2008).
A meta-analysis from 2012 suggested that risk of pancreatic can-
cer initially increases with cigarette amount but levels off at higher
intensities of cigarette smoking, indicating that quantity has some
role in determining risk (Zou et al., 2014).
Ameta-analysis from 2010 found that individuals with chronic
pancreatitis had a 13.3-fold higher risk of developing pancre-
atic cancer and a 5.8-fold increased risk after excluding cases
diagnosed within 2 years of cancer diagnosis (Raimondi et al.,
2010). However, despite this strong relationship, only about 5%
of patients with chronic pancreatitis will actually develop pancre-
atic cancer in a 20 year period (Raimondi et al., 2010). Hereditary
pancreatitis is a rare autosomal dominant disease due to a muta-
tion in the gene encoding trypsinogen in which patients develop
chronic pancreatitis at a young age (under 30). The cumulative
risk of developing pancreatic cancer is 40% by age 70 (Lowenfels
et al., 1997).
A recent meta-analysis which evaluated risk based on different
intensities of alcohol consumption provided evidence that heavy
alcohol consumption (defined as >3 drinks per day) increases
risk for pancreatic cancer by 22%, independent of tobacco
use, whereas moderate alcohol consumption did not carry an
increased risk (Tramacere et al., 2010).
Another important risk factor is body mass index, which has
been associated with an elevated risk of pancreatic cancer in sev-
eral studies (Larsson et al., 2007; Arslan et al., 2010; Jiao et al.,
2010; Genkinger et al., 2011). In a pooled analysis of 14 cohort
studies, risk for pancreatic cancer was 47% greater for individu-
als with BMI>30. Higher waist to hip ratio was also found to be
positively associated with pancreatic cancer, suggesting that cen-
tral obesity in particular may confer risk (Genkinger et al., 2011).
Lastly, a recent meta-analysis involving more than 3-million indi-
viduals identified tobacco use, obesity, and heavy alcohol, among
a host of other factors, as the 3 most important risk factors for
pancreatic cancer while vegetable and fruit consumption offered
the greatest protection against pancreatic diseases (Alsamarrai
et al., 2014).
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DIABETES AND PANCREATIC CANCER
DIABETES MELLITUS AS A RISK FACTOR FOR PANCREATIC CANCER
Diabetes mellitus (DM) or glucose intolerance may be present in
up to 75%of patients with pancreatic cancer, a figuremuch higher
than in other cancer types in whom the prevalence is no more
than 30% (Permert et al., 1993b; Aggarwal et al., 2013). The rela-
tionship between DM and pancreatic cancer is bi-directional, as
studies point to both increased risk of pancreatic cancer in those
with long-term diabetes, as well as greater incidence of diabetes in
sync with the development of pancreatic cancer (Li, 2012). Many
studies evaluating DM as a risk factor have focused on patients
with DM diagnosed several years prior to the time of pancreatic
cancer diagnosis in order to exclude cases of DM that are a result
of pancreatic cancer. This follows from the assumption that pan-
creatic cancer is rapidly fatal and therefore DM diagnosed several
years prior to cancer diagnosis would unlikely be from the cancer
(Li, 2012).
In a recent pooled analysis, after adjusting for age, gender,
prior involved study, alcohol use, smoking, BMI, and family his-
tory of pancreatic cancer, patients with DM had a 40% increased
risk of pancreatic cancer (Elena et al., 2013). This analysis
excluded cases developing within 2 years, providing evidence for
DM as a risk factor rather than just a result of pancreatic can-
cer. A meta-analysis of 20 studies conducted in 1995 showed that
patients with DM for 5 or more years had a two-fold increased
risk (Everhart and Wright, 1995). In another 2005 meta-analysis
which included 36 studies, individuals with DM for>5 years had
a 50% increased risk of pancreatic cancer (Huxley et al., 2005).
Diabetes is characterized by hyperglycemia and insulin resistance,
which can both contribute to tumor formation. In a prospective
nested case-control study, higher levels of proinsulin, a marker
of peripheral insulin resistance, was found to be associated with
pancreatic cancer, independent of hemoglobin A1c, suggesting
that insulin resistance may be a stronger carcinogenic contribu-
tor than hyperglycemia (Wolpin et al., 2013). This finding was
supported by the fact that lower levels of adiponectin, which func-
tions to enhance insulin sensitivity, was associated with increased
pancreatic cancer risk (Bao et al., 2013).
MECHANISMS OF RISK
DM and associated obesity may lead to increased risk for cancer
through several mechanisms (Figure 1). Individuals with DM2
often have peripheral insulin resistance and develop compen-
satory hyperinsulinemia (Godsland, 2009). Insulin is a growth
promoting hormone and acts by increasing cell proliferation,
decreasing apoptosis, increasing glucose utilization, and enhanc-
ing responsiveness to other growth factors; all of these actions
are important for cancer progression (Ding et al., 2000; Draznin,
2011). Insulin also decreases insulin-like growth factor (IGF)
binding protein production thereby increasing the amount of
bioavailable IGF-1 (Powell et al., 1991). IGF-1 is a more potent
mitogen than insulin and promotes pancreatic cancer cell pro-
liferation and invasion while inhibiting the tumor suppressor
phosphatase and tensin homolog (PTEN, Ma et al., 2010). IGF-
1 receptor binding leads to activation of the PI3K/Akt and
the Raf/MAPK pathways, which promote cell proliferation and
inhibit apoptosis (Pollak et al., 2004).
DM and obesity are associated with other hormonal alter-
ations that may promote neoplasia as well. Adiponectin is a
hormone that has been shown to limit angiogenesis, promote
apoptosis, and decrease inflammation. DM is associated with low
circulating levels of adiponectin, an effect that may promote car-
cinogenesis (Bao et al., 2011). Leptin is a mitogenic hormone
which is increased in obesity. It promotes angiogenesis, inhibits
apoptosis, and activates the PI3K/Akt and STAT pathways, which
promote cell growth and survival (Bao et al., 2011).
PANCREATIC CANCER-ASSOCIATED DIABETES MELLITUS
Several studies have suggested that DM is not just a risk factor,
but also a consequence of pancreatic cancer. One study looked at
the temporal association between DM and pancreatic cancer and
found a marked increase in cases of DM starting at 36 months
prior to diagnosis, with cases continuing to increase up to cancer
diagnosis, suggesting that the cancer itself was likely the etiologic
factor (Chari et al., 2008). A meta-analysis of 35 cohort studies
showed DM was associated with a 94% increased risk of pancre-
atic cancer. Interestingly, risk decreased with duration of diabetes
(5.38 for <1 year, 1.95 for 1–4 years, 1.49 for 5–9 years, 1.47
for ≥10 years) providing support that much of diabetes in pan-
creatic cancer patients is caused by the cancer itself (Ben et al.,
2011).
Pancreatic cancer-induced DM is thought to be a paraneoplas-
tic phenomenon involving release of products from the tumor
rather than a result of destruction of the pancreas due to malig-
nant infiltration (Pannala et al., 2008; Aggarwal et al., 2012).
This hypothesis is supported by a study which showed that the
prevalence of DM in patients with pancreatic cancer was not
related to tumor stage or location, as would be expected if the
DM were a result of tumor infiltration (Pannala et al., 2008).
Furthermore, several studies have shown resolution of DM after
tumor resection in individuals with pancreatic cancer (Permert
et al., 1993a; Fogar et al., 1994; Pannala et al., 2008; White et al.,
2011). A study by Aggarwal et al. (2012) showed that the hor-
mone adrenomedullin is upregulated at the mRNA and protein
level in pancreata from patients with pancreatic cancer. In vitro
studies indicate that adrenomedullin impairs glucose-stimulated
insulin secretion in β-cells, and adrenomedullin overexpression
in mouse pancreatic cancer tissues is associated with increased
glucose intolerance suggesting that adrenomedullin is an impor-
tant mediator of cancer-induced DM (Aggarwal et al., 2012).
Other potential mediators found upregulated in pancreatic cancer
include S-100A8 N-terminal peptide, which was shown to alter
glucose catabolism in vitro (Basso et al., 2006), and islet amyloid
polypeptide which causes insulin resistance (Permert et al., 1994).
One review suggested that pancreatic cancer-associated insulin
resistance may be mediated by release of cytokines, adipokines,
and non-esterified fatty acids from adipose tissue inflammation
(Sah et al., 2013).
STANDARDS OF THERAPY
Surgical resection is the only cure for pancreatic adenocarcinoma
although 80% of patients have unresectable disease at the time
of presentation (Campen et al., 2011). Pancreaticoduodenectomy
and distal pancreatectomy with or without splenectomy are
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FIGURE 1 | Metformin demonstrates antitumor properties through
several pathways. Diabetes mellitus type 2 (DM2) is often characterized by
insulin resistance, hyperglycemia, and compensatory hyperinsulinemia.
Insulin increases IGF-1 levels by displacing IGF-1 from common binding
proteins, stimulating hepatic growth hormone signaling, and decreasing
IGF-binding protein production. Like other growth factors, insulin and IGF-1,
upon binding to their respective growth factor receptors, can promote
pancreatic cancer development through MAPK/ERK or Ras/Raf/MEK/ERK
signaling and PI3K/Akt/mTOR signaling. For example, IGF-1 binding to the
IGF-1 receptor recruits and activates PI3K via adaptor proteins such as IRS,
converts PIP2 to PIP3 (a process that is inhibited by PTEN), activates
Akt/PKB through PDK1- and mTORC2-mediated phosphorylation, and inhibits
formation of TSC1-TSC2 thereby releasing its inhibition on Rheb (an
mTORC1 activator). Activated mTORC1 is a key regulator of cell growth,
metabolism, survival, and proliferation through downstream mediators such
as 4EBP1 and S6K. Metformin has been known to uncouple the electron
transport chain at complex I leading to decreased ATP production and
activation of LKB1 and AMPK. AMPK is a stabilizer of TSC1-TSC2 and
activator of p53, a tumor suppressor. Independent of AMPK, metformin
increases p53-dependent expression of REDD1, an inhibitor of mTORC1,
and inhibits mTORC1 by inhibiting Rags. Metformin also reduces
hyperinsulinemia and IGF-1 levels and offers further antitumor effects by
reducing levels of Shh, HMGA1, ROS, Sp transcription factors, Sp-related
oncogenic proteins (cyclin D1, VEGF, survivin, Bcl-2, FAS), and HIF-1α
through relatively unknown mechanisms. Dashed lines represent putative or
suggested pathways while red lines represent inhibitory pathways. IGF-1,
insulin-like growth factor-1; IRS, insulin receptor substrate; PI3K,
phosphoinositide 3-kinase; PIP2, phosphatidylinositol-4,5-bisphosphate;
PTEN, phosphatase and tensin homolog; MAPK, mitogen-activated protein
kinase; MEKs, MAPK kinases; ERKs, extracellular signal regulated kinases;
PDK1, phosphoinositide-dependent kinase 1; PKB, protein kinase B or Akt;
TSC1, tuberous sclerosis complex 1; Rheb, Ras homolog enriched in brain;
mTOR, mammalian target of rapamycin; 4EBP1, eukaryotic initiation factor
4E binding protein 1; S6K, S6 kinase; AMP, adenosine monophosphate;
LKB1, liver kinase B1; AMPK, AMP-activated protein kinase; AAs, amino
acids; Rags, Rag GTPases; REDD1, regulated in development and DNA
damage responses 1; Shh, Sonic hedgehog; HMGA1, high mobility group
AT-hook 1; ROS, reactive oxygen species; Sp, specificity protein; VEGF,
vascular endothelial growth factor; Bcl-2, B-cell lymphoma-2; HIF-1α,
hypoxia-inducible factor-1 alpha; FAS, fatty acid synthase.
performed in patients with tumors in the head and body/tail of
the pancreas, respectively (De La Cruz et al., 2014). Given that
median survival is poor even in patients that undergo surgical
resection, most patients are offered adjuvant chemotherapy with
gemcitabine or fluorouracil ± chemoradiation (De La Cruz et al.,
2014).
Patients with locally advanced, unresectable, or borderline
resectable disease may receive neoadjuvant chemotherapy ±
radiotherapy in an attempt to downstage the disease (Seufferlein
et al., 2012). For metastatic disease, treatment options address
palliation and improved survival. Gemcitabine has been used
to treat metastatic pancreatic adenocarcinoma since 1997 when
it produced a one year survival benefit compared to 5-FU and
remains the chemotherapy of choice in patients with poor func-
tional status and advanced disease (Burris et al., 1997; Ghosn
et al., 2014). In 2011, FOLFIRINOX (fluorouracil, leucovorin,
irinotecan, and oxaliplatin) produced a significant survival ben-
efit compared to patients treated with gemcitabine monotherapy
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(Conroy et al., 2011). Gemcitabine plus nab-paclitaxel produces
less adverse effects than FOLFIRINOX and offers the second best
overall survival in those with good functional status (Ghosn et al.,
2014). Gemcitabine plus erlotinib shows improved survival vs.
monotherapy, but survival benefit remains minimal (Ghosn et al.,
2014). Despite the fact that chemotherapy confers some survival
benefit, this benefit is modest and exploration of new therapies is
essential.
METFORMIN AND PANCREATIC CANCER
METFORMIN REDUCES RISK FOR PANCREATIC CANCER
Metformin is one of the most widely prescribed oral agents for
the treatment of DM2. Evans et al. (2005) were among the first
to suggest metformin as an anti-cancer therapy. However, as early
as 2001, one study demonstrated that metformin prevented pan-
creatic cancer development in hamsters treated with a pancreatic
carcinogen (Schneider et al., 2001). A study in 2009 with 62,809
patients compared cancer risk in patients on different kinds of
diabetic therapies and found that insulin therapy increased the
risk of pancreatic cancer compared to metformin therapy (Currie
et al., 2009). Furthermore, compared to patients that were on
insulin alone, patients with metformin added to insulin had a sig-
nificantly reduced risk of developing solid tumors (Currie et al.,
2009). A recent meta-analysis showed that patients with dia-
betes who were taking metformin had a significantly reduced risk
of pancreatic cancer (Wang et al., 2014). Consistent with this
finding, an observational study of 302 diabetic patients with pan-
creatic cancer found that metformin users showed significantly
increased survival times as compared to non-users (15.2 months
vs. 11.1 months, Sadeghi et al., 2012).
MECHANISMS OF ACTION
Although there is much to be learned about metformin’s mech-
anism of action in cancer (Figure 1), most studies suggest that
metformin acts primarily through its effect on AMP-activated
protein kinase (AMPK, Kalender et al., 2010; Ben Sahra et al.,
2011). Metformin inhibits complex I of the electron transport
chain (El-Mir et al., 2000), which decreases adenosine triphos-
phate (ATP) production and leads to AMPK activation. AMPK
activation leads to disruption of insulin/IGF-1 signaling through
inhibition of mammalian target of rapamycin (mTOR, Rozengurt
et al., 2010). Inhibition of mTOR signaling, in turn, results in
decreased protein synthesis and cell growth, which are important
for cancer survival (Figure 1). Metformin can also inhibit mTOR
signaling through activation of AMPK independent pathways
including Rag GTPase (Kalender et al., 2010) and REDD1 (Ben
Sahra et al., 2011). AMPK-induced activation of tumor suppres-
sor 53 (p53) and subsequent cell cycle arrest represents another
potential mechanism of action of metformin in pancreatic can-
cer models (Jalving et al., 2010). Activation of AMPK in the liver,
muscle, adipose tissue, and pancreas also results in reduced levels
of insulin and IGF-1 (Jalving et al., 2010).
Indeed, mTOR and mitochondrial energy signaling path-
ways have increasingly been the focus of recent investigations
on the antitumor properties of metformin in pancreatic cancer.
Early studies demonstrated that metformin induced inhibition
of mTORC1 activity and growth of human pancreatic cancer
xenografts (Kisfalvi et al., 2009). Concentrations of metformin
approximate to plasma levels found in patients with DM2 tak-
ing the drug (0.05mM or 0.1mM) similarly inhibited mTORC1
activity in a dose-dependent manner in vitro (Sinnett-Smith et al.,
2012). Interestingly, metformin-inducedmTORC1 inhibition was
significantly enhanced in pancreatic cancer cells cultured in
physiologic glucose concentrations (5mM) compared to supra-
physiologic levels (25mM) highlighting the concept that cancer
cells, at lower ambient glucose concentrations, rely more onmito-
chondrial oxidative phosphorylation for ATP generation and are
therefore more sensitized to mitochondrial respiration inhibitors
(Sinnett-Smith et al., 2012; Rozengurt, 2014). Furthermore, syn-
ergistic enhancements in ATP depletion and pancreatic cancer
cell growth suppression were demonstrated when metformin
was added to an inhibitor of glycolysis, 2-deoxyglucose (2-DG),
in vitro (Cheng et al., 2014).
Recent studies have shown that pancreatic cancer cell growth
(in vitro and in vivo) is also dependent on glutamine metabolism
reprogrammed by oncogenic Kras via a unique pathway involv-
ing aspartate transaminase (GOT1) that leads to a maintenance
of essential cellular redox states in the mitochondria (Son et al.,
2013). Moreover, pancreatic cancer cells responsible for relapse
that survive oncogene ablation have increased expression of genes
involving mitochondrial function and reliance on glycolysis and
mitochondrial respiration for energy metabolism in Kras mouse
models (Viale et al., 2014). These latest insights offer exciting
future therapeutic strategies in pancreatic cancer by targetingKras
signaling in combination with using mitochondrial respiration
inhibitors such asmetformin. Further identification of novel ther-
apeutic targets will rely, as they have before, on the development
of tools critical to our understanding of pancreatic cancer such as
genetically engineered mouse models (GEMMs) like the KrasG12D
and embryonic stem cell (ESC)-based mouse models (Kirk, 2012;
Saborowski et al., 2014).
Rapamycin and active-site mTOR inhibitors have been shown
to increase Akt phosphorylation and ERK activation in pancre-
atic cancer cells in vitro, respectively, and highlight the feedback
mechanisms that potentially counterbalance the antitumor
effects of mTOR inhibitors (Soares et al., 2013). Metformin’s
antitumor effects, however, occur without stimulating Akt
and ERK activation, and therefore, metformin in combination
with mTOR inhibitors represents a future direction to improve
clinical efficacy in pancreatic cancer (Soares et al., 2013). Indeed,
metformin with rapamycin is now under ongoing clinical
investigation (phase I and II) in the treatment of advanced
pancreatic cancer (NCT02048384). Of note, PTEN deficiencies in
KrasG12D mice models have been shown to promote NF-κB and
associated cytokine activation and development of metastatic
pancreatic cancer (Ying et al., 2011). Treatment with rapamycin
conferred a significant survival advantage in Kras mice models
deficient of PTEN compared to those lacking PTEN deficiencies
in vivo (Morran et al., 2014). These studies intriguingly identify
particular subsets of pancreatic cancer, those with Krasmutations
and PTEN deficiencies, that may be more responsive to treatment
with mTOR inhibitors and/or inhibitors of MAPK/ERK,
PI3K, and NF-κB (mediators of converging signaling
pathways).
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Table 1 | The preclinical development of metformin in pancreatic
cancer.
Study Source in which metformin demonstrated
antitumor activity
Cheng et al., 2014 MiaPaCa-2 and Capan-2 cells (in vitro, ± glycolytic
inhibitor 2-DG)
Das et al., 2014 Panc-1 and AsPC-1 cells (in vitro)
Fasih et al., 2014 Panc-1 and MiaPaCa-2 cells (in vitro, ± ionizing
radiation ± gemcitabine)
Nair et al., 2014 Panc-28, L3.6pL, and Panc-1 cells (in vitro)
Snima et al., 2014 MiaPaCa-2 cells (in vitro, in metformin-containing
O-carboxymethyl chitosan nanoparticles)
Yue et al., 2014 BxPC-3 and Panc-1 cells (in vitro, + aspirin)
Gou et al., 2013 AsPC-1 and SW1990 cells (in vitro) and AsPC-1 and
SW1990 tumor xenografts in nude mice (in vivo)
Karnevi et al., 2013 BxPC-3, Panc-1, and MiaPaCa-2 cells (in vitro)
Kisfalvi et al., 2013 Panc-1 and MiaPaCa-2 tumor xenografts in nude
mice (in vivo)
Lonardo et al.,
2013
Primary human pancreatic ductal adenocarcinoma
(PDAC) cells and spheres (in vitro, ± gemcitabine)
and tumor xenografts in nude mice (in vivo, ±
gemcitabine and smoothened inhibitor SIBI-C1)
Nair et al., 2013 Panc-28, Panc-1, and L3.6pL cells (in vitro) and
L3.6pL tumor xenografts in nude mice (in vivo)
Soares et al., 2013 Panc-1 cells (in vitro)
Yan et al., 2013 MiaPaCa and KP cells (in vitro)
Bao et al., 2012 Gemcitabine-sensitive and gemcitabine-resistant
AsPC-1 and MiaPaCa-2 cells (in vitro) and
MiaPaCa-2 tumor xenografts in mice (in vivo)
Li et al., 2012 Sw1990 tumor xenografts in nude mice (in vivo)
Sinnett-Smith
et al., 2012
Panc-1 and MiaPaCa-2 cells (in vitro)
Snima et al., 2012 MiaPaCa-2 cells (in vitro, in metformin-containing
O-carboxymethyl chitosan nanoparticles)
Kisfalvi et al., 2009 Panc-1 and MiaPaCa-2 tumor xenografts in nude
mice (in vivo)
Wang et al., 2008 SW1990, AsPC-1, BxPc-3, and Panc-1 cells (in vitro)
Other studies have shown that metformin treatment leads
to downregulation of members of the specificity protein (Sp)
transcription factor family and target genes involved in tumori-
genesis including Bcl-2, survivin, cyclin D1, vascular endothelial
growth factor, and fatty acid synthase (FAS, Nair et al., 2013,
2014). In particular, decrease in cyclin D1 induced cell cycle
arrest in prostate cancer cells (Ben Sahra et al., 2008). Metformin
may also inhibit FAS in the context of available cholesterol and
glucose-derived acetyl-CoA in pancreatic cancer cells (Cantoria
et al., 2014). In addition, in vitro studies showed that metformin
alters profiles of microRNAs that regulate apoptosis, inhibit pro-
liferation and invasion, and are linked to reduced expression
of the oncogene HMGA1 (Li et al., 2012). Metformin can also
affect proliferation of cancer stem cells, and this effect may con-
tribute to its ability to limit tumor growth (Gou et al., 2013).
Other potential anti-tumorigenic effects of metformin include
the ability to reduce endogenous reactive oxygen species (ROS)
and associated DNA damage (Algire et al., 2012), reduce Sonic
hedgehog (Shh) expression (Nakamura et al., 2014), and induce
anti-inflammatory responses (Cufí et al., 2010; Hirsch et al., 2013;
Zhao et al., 2014).
Metformin has demonstrated antitumor activity against pan-
creatic cancer in numerous preclinical studies (Table 1). A recent
study highlighted the ability of metformin to prevent progres-
sion of pancreatic intraepithelial neoplasia (PanIN) lesions to
pancreatic cancer in transgenic mice as well (Mohammed et al.,
2013). There are several clinical trials (phase I and II, https://
clinicaltrials.gov) involving metformin in the treatment of pan-
creatic cancer. The majority involve metformin in combination
therapies, given that metformin is unlikely to produce a desired
efficacy to serve as monotherapy in pancreatic cancer. However,
its attractiveness as part of combinatorial therapy lies, in part, in
its inexpensiveness (as low as $4 per month) and well-tolerated
toxicity profile (common toxicities being gastrointestinal). As dis-
cussed above, metformin offers synergistic activity across several
but converging signaling pathways important to tumorigenesis.
Addition of metformin may also reduce effective doses of other
chemotherapeutic agents needed to treat a variety of cancers
(Iliopoulos et al., 2011).
Undoubtedly, there remains a need for further understanding
of: (1) anticancer mechanisms of metformin, particularly those
involving, but not limited to, mTOR signaling (upstream and
downstream) and mitochondrial energy metabolism, (2) phar-
macokinetic and pharmacodynamic properties of metformin,
and (3) relationships between risk factors such as DM and devel-
opment and progression of pancreatic cancer to identify further
molecular targets and advance potential therapies. For now, the
future remains bright for metformin as the scientific commu-
nity eagerly awaits the results of its continued development as a
treatment for pancreatic cancer.
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